pembrolizumab,dostarlimab
Merck,gsk
['zenocutuzumab', 'destiny,crc,01', 'key,note,52', 'nsclc', 'pemigatinib', 'keynote,54', 'sclc', 'ca,022,i', 'optima', 'lapati', 'pivot,9', 'gi ', 'ca,022,1', 'key,note,45', 'breast', 'pivot,io,i', 'key,note,62', 'key,note,42', 'sarcoma', 'nci-match', 'destiny,breast,4', 'destiny,breast,2', 'bemarituzumab', 'friends', 'bladder', 'toripalimab', 'ca,022,001', 'paradigm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'dostarlimab', ' futi', 'evolve,msi', 'renal,(-adrenal)', 'gastric', 'larotrectinib', 'esophageal', 'tucatinib', 'alofanib', 'colorectal', 'margetuximab', 'keynote,91', 'pembro', 'apatinib', 'futibatinib', 'afatinib', 'key,note,48', 'pralsetinib', 'gastroesophageal', 'destiny,lung,4', 'fam-trastuzumab', 'destiny,breast,3', 'trastuzumab deruxtecan', 'oreo', 'destiny,breast,6', 'deep,lung,4', 'biomarker', 'melanoma', 'vemurafenib', 'deep,lung,iv', 'trametinib', 'libretto-001', 'dabrafenib', 'rux,(-crux),(-trux)', 'dance', 'key,note,24', 'selpercatinib', 'rectal', 'keynote-164', 'lung', 'entrectinib', 'solid tumor', 'pancreatic', 'key,note,57', 'keynote-158', 'pertuzumab', 'marker ', 'novo ', 'adaptive ']
 impact of tissue-agnostic approvals in gi malignancies 5 : ntrk, ret, msi, tmb high, braf v600e more to come: fgfr, her2/erbb2, nrg1, ras (?) open : tmb cut off, tumor specific moa resistance, ngs for all? 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine